We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long-Term Results of Concurrent Chemoradiotherapy Combined with Anti-EGFR Monoclonal Antibody Prior to Surgery in Locally Advanced Cervical Cancer: A Single-Institute Prospective Study.
- Authors
Qing, Defeng; Wu, Yuying; Liu, Xu; Jiang, Hailan; Zhu, Chaohua; Liu, Pei; Dang, Junming; Li, Xianglong; Chen, Zhaohong; Long, Xianfeng; Pang, Qiang; Peng, Luxing; Deng, Shan; Gu, Junzhao; Zhao, Renfeng; Chen, Changyi; Lu, Heming
- Abstract
Purpose: We aimed to evaluate the long-term survival outcomes of concurrent chemoradiotherapy (CCRT) combined with nimotuzumab followed by surgery in patients with locally advanced cervical cancer (LACC). Patients and Methods: Patients received whole pelvic intensity-modulated radiation therapy (IMRT) and concomitantly with weekly cisplatin (40 mg/m2) or nedaplatin (30 mg/m2) and weekly nimotuzumab (200 mg). After assessment of the treatment response, patients then underwent radical surgery. Results: Between June 2013 and July 2016, 33 patients with FIGO IB2–IIIB cervical cancer were recruited. Clinical complete response and partial response were observed in 8 (24.3%) and 23 patients (69.7%), respectively. Twenty-seven patients (81.8%) were successfully treated with radical hysterectomy and pelvic lymphadenectomy: 9 (33.3%) showed pathological complete response; 10 (37.1%) showed partial response and 8 (29.6%) presented with persistent macroscopic/microscopic residual carcinoma. For the intention-to-treat population, the median follow-up time was 53.7 months. Locoregional recurrence and distant metastases were observed in three and seven patients, respectively. The 5-year overall survival, progression-free survival, locoregional recurrence-free survival, and distant metastasis-free survival were 81.5%, 72.7%, 90.9%, and 78.3%, respectively. Both acute and late toxicities were manageable and mainly limited to grade 1 or 2. Conclusion: Concurrent chemoradiotherapy combined with nimotuzumab followed by surgery for patients with LACC is safe and results in excellent long-term treatment outcomes. Further randomized controlled studies are warranted to confirm the findings.
- Subjects
CHEMORADIOTHERAPY; CERVICAL cancer; MONOCLONAL antibodies; LONGITUDINAL method; PROGRESSION-free survival; SURGERY
- Publication
Cancer Management & Research, 2020, Vol 12, p12309
- ISSN
1179-1322
- Publication type
Article
- DOI
10.2147/CMAR.S282372